Title: PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder
cancer: A retrospective comparative study
Version: 3 Date: 08 Sep 2024
Reviewer:  Hiroki Ueda
Reviewer's report:
This study was a single-center trial based on clinical practice. The combination of tislelizumab
and GS chemotherapy is a safe and more effective treatment option for patients with advanced
GBC. This paper is significant in demonstrating the safety and efficacy of combining
tislelizumab and GS and was well-understood. However, I believe some revisions are needed
for publication. Below are the points that require correction:
1. This study demonstrated that the combination of tislelizumab and GS chemotherapy showed
better therapeutic efficacy for advanced GBC compared to the combination of tislelizumab and
Lenvatinib. However, it seems that the underlying reasons for this difference have not been
sufficiently discussed. Further discussion is needed on the improvement in therapeutic effect of
tislelizumab and GS chemotherapy.
2. In this study, both the combination therapy of tislelizumab with GS and the combination of
tislelizumab with Lenvatinib were administered, but was this conducted as first-line therapy for
advanced GBC? If so, it would be important to include details about any differences between
the two groups in terms of second-line therapies and beyond.
Title: PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder
cancer: A retrospective comparative study
Version: 3 Date: 08 Sep 2024
Reviewer:  Hiroki Ueda
Reviewer's report:
This study was a single-center trial based on clinical practice. The combination of tislelizumab
and GS chemotherapy is a safe and more effective treatment option for patients with advanced
GBC. This paper is significant in demonstrating the safety and efficacy of combining
tislelizumab and GS and was well-understood. However, I believe some revisions are needed
for publication. Below are the points that require correction:
1. This study demonstrated that the combination of tislelizumab and GS chemotherapy showed
better therapeutic efficacy for advanced GBC compared to the combination of tislelizumab and
Lenvatinib. However, it seems that the underlying reasons for this difference have not been
sufficiently discussed. Further discussion is needed on the improvement in therapeutic effect of
tislelizumab and GS chemotherapy.
2. In this study, both the combination therapy of tislelizumab with GS and the combination of
tislelizumab with Lenvatinib were administered, but was this conducted as first-line therapy for
advanced GBC? If so, it would be important to include details about any differences between
the two groups in terms of second-line therapies and beyond.
Please review this paper.
user
Title: PD-1 inhibitors combined with chemotherapy or lenvatinib in advanced gallbladder
cancer: A retrospective comparative study
Version: 3 Date: 08 Sep 2024
Reviewer:  Hiroki Ueda
Reviewer's report:
This study was a single-center trial based on clinical practice. The combination of tislelizumab
and GS chemotherapy is a safe and more effective treatment option for patients with advanced
GBC. This paper is significant in demonstrating the safety and efficacy of combining
tislelizumab and GS and was well-understood. However, I believe some revisions are needed
for publication. Below are the points that require correction:
1. This study demonstrated that the combination of tislelizumab and GS chemotherapy showed
better therapeutic efficacy for advanced GBC compared to the combination of tislelizumab and
Lenvatinib. However, it seems that the underlying reasons for this difference have not been
sufficiently discussed. Further discussion is needed on the improvement in therapeutic effect of
tislelizumab and GS chemotherapy.
2. In this study, both the combination therapy of tislelizumab with GS and the combination of
tislelizumab with Lenvatinib were administered, but was this conducted as first-line therapy for
advanced GBC? If so, it would be important to include details about any differences between
the two groups in terms of second-line therapies and beyond.
assistant